BioSante reports good results from phase II AML vaccine study
BioSante Pharmaceuticals is reporting positive results from a Phase II study investigating their GVAX Vaccine for acute myeloid leukemia. The company also learned that the FDA has granted GVAX Orphan Drug Status.
In the Phase II study, published in Blood, 85% of patients achieved a complete response to the therapy, which included the vaccine, immunotherapy-primed lymphocytes and an autologous stem cell transplantation.
BioSante is slowly building up a portfolio of cancer drugs: the company's GVAX Pancreas Vaccine was recently given Orphan Drug Status, and it currently has a 'vaccine' in clinical trials for breast cancer.
With few exceptions, true cancer vaccines have proven elusive for researchers, as they are unable to rouse a response from the immune system to attack the body's cancerous cells because those cells manage to escape detection.
Source: BioSante
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
